Literature DB >> 11413785

The Gordon Wilson Lecture: viruses and human disease.

G J Nabel1.   

Abstract

In many ways, Ebola virus infection provides a model for understanding the toxicity of viruses and their causal role in human disease. The highly aggressive course of Ebola virus infection provides a model for understanding the molecular mechanisms of viral cytotoxicity. In addition, the use of animal models and definition of immune correlates, which lead to protection, may provide lessons that are applicable to other viral infections. Perhaps the greatest challenge facing biomedical science today is the containment of the human immunodeficiency virus, the causative agent of AIDS. In many ways the critical obstacles to the development of a vaccine for HIV are similar to those observed with Ebola virus infection. Because the reservoir of infection is not known and human-to-human spread has been documented, vaccines may provide the best opportunity to contain and limit the spread of infection worldwide. Similar to Ebola virus, there are few convincing examples of immune resistance of HIV infection. In addition, it has been difficult to identify broadly neutralizing antibodies that can prevent infection in vitro or in vivo. In defining immune correlates, relevant animal models, and mechanisms of cytotoxicity, it is hoped that similar efforts may lead to effective vaccines for other infectious diseases. In this way, Ebola virus infection provides a useful paradigm for understanding the genetic determinants of viral disease and in facilitating the development of treatments and prevention of viral infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413785      PMCID: PMC2194412     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  25 in total

1.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

3.  Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors:  B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

4.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

5.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Expression of hepatitis B surface antigen with a recombinant adenovirus.

Authors:  A R Davis; B Kostek; B B Mason; C L Hsiao; J Morin; S K Dheer; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

Authors:  M Sedegah; R Hedstrom; P Hobart; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein.

Authors:  H Feldmann; S T Nichol; H D Klenk; C J Peters; A Sanchez
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

10.  Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Authors:  R J Natuk; P K Chanda; M D Lubeck; A R Davis; J Wilhelm; R Hjorth; M S Wade; B M Bhat; S Mizutani; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.